<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217136</url>
  </required_header>
  <id_info>
    <org_study_id>7625A-035</org_study_id>
    <secondary_id>2016-004820-41</secondary_id>
    <nct_id>NCT03217136</nct_id>
  </id_info>
  <brief_title>MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)</brief_title>
  <official_title>A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Pediatric Subjects With Complicated Intra-Abdominal Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam)&#xD;
      plus metronidazole, compared with that of meropenem in pediatric participants with cIAI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Actual">March 16, 2020</completion_date>
  <primary_completion_date type="Actual">March 16, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with ≥1 adverse events (AEs)</measure>
    <time_frame>Up to Day 42</time_frame>
    <description>The number of participants with one or more AEs will be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants discontinuing study therapy due to AE(s)</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>The number of participants who discontinued study drug due to an AE will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a clinical response of cure</measure>
    <time_frame>Up to Test of Cure Visit (up to 28 days)</time_frame>
    <description>The percentage of participants who have a clinical response of cure will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with microbiological eradication of all baseline pathogens</measure>
    <time_frame>Up to Test of Cure Visit (up to 28 days)</time_frame>
    <description>The percentage of participants who have microbiological eradication or presumed eradication of all baseline pathogens will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Complicated Intra-Abdominal Infection</condition>
  <arm_group>
    <arm_group_label>Ceftolozane/Tazobactam + Metronidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1 g/dose and tazobactam 0.5 g/dose); plus Metronidazole 10 mg/kg (maximum 1.5 g/day) administered intravenously (IV) every 8 to 12 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 5 days and a maximum of 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem + Placebo for Metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meropenem 20 mg/kg (maximum 1 g/dose) plus placebo for Metronidazole administered IV every 8 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 5 days and a maximum of 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane</intervention_name>
    <description>Ceftolozane 20 mg/kg (maximum 1 g) administered IV every 8 hours for between 5 to 14 day.</description>
    <arm_group_label>Ceftolozane/Tazobactam + Metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazobactam</intervention_name>
    <description>Tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 5 to 14 days.</description>
    <arm_group_label>Ceftolozane/Tazobactam + Metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Metronidazole 10 mg/kg (maximum 1.5 g/day) administered IV every 8 hours for between 5 to 14 days. Participants =&lt; 28 days old, start with a loading dose of 15 mg/kg; then if =&lt; 2 kg are dosed 7.5 mg/kg/ every 12 hours; or if &gt; 2 kg are dosed 10 mg/kg every 8 hours.</description>
    <arm_group_label>Ceftolozane/Tazobactam + Metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 5 to 14 days. At the investigator's discretion, some participants may receive meropenem up to 30 mg/kg.</description>
    <arm_group_label>Meropenem + Placebo for Metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Metronidazole</intervention_name>
    <description>Placebo for Metronidazole administered IV every 8 hours for between 5 to 14 days.</description>
    <arm_group_label>Meropenem + Placebo for Metronidazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a legally acceptable representative who provides documented informed&#xD;
             consent/assent for the trial.&#xD;
&#xD;
          -  Aged from birth (defined as &gt;32 weeks gestational age and ≥7 days postnatal) to &lt;18&#xD;
             years of age.&#xD;
&#xD;
          -  Require IV antibacterial therapy for the treatment of presumed or documented cIAI.&#xD;
&#xD;
          -  Has an operative procedure for the current diagnosis and management of cIAI planned or&#xD;
             completed within 24 hours of the first dose of an antibacterial drug. Note:&#xD;
             Participants with a diagnosis of necrotizing enterocolitis are exempt and not required&#xD;
             to have surgery planned or completed in order to be eligible.&#xD;
&#xD;
          -  Has in compliance baseline intra-abdominal specimen collection.&#xD;
&#xD;
          -  Is not of reproductive potential; but if of reproductive potential agrees to avoid&#xD;
             becoming pregnant or impregnating a partner during screening, while receiving study&#xD;
             treatment and for at least 30 days after the last dose of study treatment.&#xD;
&#xD;
          -  Female of reproductive potential is not pregnant, and not planning to become pregnant&#xD;
             within 30 days of the last day of treatment administration; and is nonlactating.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is currently participating in or has participated in an interventional clinical trial&#xD;
             with an investigational compound or device within 30 days prior to the first dose of&#xD;
             study treatment in this current trial.&#xD;
&#xD;
          -  Has previously participated in any trial of ceftolozane or ceftolozane/tazobactam or&#xD;
             has enrolled previously in the current trial and been discontinued.&#xD;
&#xD;
          -  Has a history of any moderate or severe hypersensitivity (eg, anaphylaxis), allergic&#xD;
             reaction, or other contraindication to any of the following: β-lactam antibiotics (eg,&#xD;
             penicillins, cephalosporins, and carbapenems), β-lactamase inhibitors (eg, tazobactam,&#xD;
             sulbactam, clavulanic acid, avibactam), or metronidazole.&#xD;
&#xD;
          -  Has an IAI within the past 1 year prior to randomization known to be caused by a&#xD;
             pathogen resistant to either IV study treatment.&#xD;
&#xD;
          -  Has a concomitant infection at the time of randomization that requires nonstudy&#xD;
             systemic antibacterial therapy in addition to IV study treatment or oral step-down&#xD;
             therapy.&#xD;
&#xD;
          -  Has received potentially therapeutic antibacterial therapy for a duration more than 24&#xD;
             hours during the 48 hours preceding the first dose of study treatment, unless is&#xD;
             considered to be failing antibiotic therapy for cIAI.&#xD;
&#xD;
          -  Has any of the following: a) intractable cIAI that the investigator anticipates would&#xD;
             require more than 14 days of study treatment; b) abdominal wall abscess; c) small&#xD;
             bowel obstruction; d) ischemic bowel disease without perforation; e) traumatic bowel&#xD;
             perforation with surgery within 12 hours of perforation; f) perforation of&#xD;
             gastroduodenal ulcers requiring surgery within 24 hours of perforation; g) suspected&#xD;
             uncomplicated intra-abdominal infection (eg, cholecystitis without rupture or&#xD;
             extension beyond the gallbladder wall); h) acute suppurative cholangitis; i) infected&#xD;
             necrotizing pancreatitis; j) pancreatic abscess.&#xD;
&#xD;
          -  Has moderate or severe impairment of renal function.&#xD;
&#xD;
          -  Has a seizure disorder or is anticipated to be treated with divalproex sodium or&#xD;
             valproic acid during the course of study treatment.&#xD;
&#xD;
          -  Is receiving, or is expected to receive, any prohibited medications.&#xD;
&#xD;
          -  Has any rapidly progressing disease or immediately life-threatening illness, including&#xD;
             acute hepatic failure, respiratory failure, or septic shock.&#xD;
&#xD;
          -  Has an immunocompromising condition.&#xD;
&#xD;
          -  Has a history of malignancy ≤5 years prior to signing informed consent.&#xD;
&#xD;
          -  Is planning to receive suppressive/prophylactic antibiotics with gram-negative&#xD;
             activity after completion of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital - Los Angeles ( Site 2508)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County ( Site 2502)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital-San Diego ( Site 2505)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center/Wolfson Children's Hospital ( Site 2521)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center-Floating Hospital for Children ( Site 2516)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital ( Site 2511)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital ( Site 2509)</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital ( Site 2500)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Childrens Hospital ( Site 2510)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pequeno Principe ( Site 0200)</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80250-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst de Medicina Integral Professor Fernando Figueira- IMIP ( Site 0201)</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50070-550</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Tacchini ( Site 0203)</name>
      <address>
        <city>Bento Goncalves</city>
        <state>Rio Grande Do Sul</state>
        <zip>95700-068</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PTE AOK Klinikai Kozpont ( Site 0805)</name>
      <address>
        <city>Pecs</city>
        <state>Baranya</state>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SzSzBMK es Egyetemi Oktatokorhaz Josa Andras Oktatokorhaz ( Site 0804)</name>
      <address>
        <city>Nyiregyhaza</city>
        <state>Szabolcs-Szatmar-Bereg</state>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem ( Site 0807)</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heim Pal Orszagos Gyermekgyogyaszati Intezet ( Site 0806)</name>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont ( Site 0801)</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 0802)</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kaunas ( Site 1001)</name>
      <address>
        <city>Kaunas</city>
        <zip>50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaipedos Vaiku Ligonine ( Site 1000)</name>
      <address>
        <city>Klaipeda</city>
        <zip>92140</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaiku Ligonine VU ligonines Santariskiu kliniku filialas ( Site 1002)</name>
      <address>
        <city>Vilnius</city>
        <zip>08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universiti Kebangsaan Malaya Medical Centre ( Site 1101)</name>
      <address>
        <city>Cheras</city>
        <state>Johor</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang ( Site 1102)</name>
      <address>
        <city>Georgetown</city>
        <state>Pulau Pinang</state>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre. ( Site 1100)</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Nino y Adolescente Morelense ( Site 1204)</name>
      <address>
        <city>Emiliano Zapata</city>
        <state>Morelos</state>
        <zip>62765</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Tecnologico y de Estudios Superiores de Monterrey ( Site 1203)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatria ( Site 1201)</name>
      <address>
        <city>Mexico City</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de Mexico Federico Gomez ( Site 1202)</name>
      <address>
        <city>Mexico City</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spit. Cl. de Urg. Copii Cluj Napoca ( Site 1703)</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400370</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii &quot;Louis Turcanu&quot; Timi ( Site 1701)</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300011</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Children Clinical Hospital ( Site 1802)</name>
      <address>
        <city>Chelyabinsk</city>
        <state>Chelyabinskaya Oblast</state>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk Regional Clinical Hospital ( Site 1800)</name>
      <address>
        <city>Smolensk</city>
        <state>Smolenskaya Oblast</state>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavropol Regional Pediatric Clinical Hospital ( Site 1805)</name>
      <address>
        <city>Stavropol</city>
        <state>Stavropol Skiy Kray</state>
        <zip>355029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Childrens Clinical Hospital ( Site 1809)</name>
      <address>
        <city>Vologda</city>
        <state>Vologodskaya Oblast</state>
        <zip>160022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Molotlegi Street ( Site 1901)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0208</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Red Cross War Memorial Children's Hospital ( Site 1902)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago ( Site 2001)</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña [La Coruña]</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d Oncologia Hospital Germans Trias i Pujol ( Site 2004)</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Sant Joan de Deu ( Site 2000)</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe ( Site 2003)</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana, Comunitat</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cukurova Uni Tip Fak Cocuk Saglıgı ve Hasta ABD ( Site 2200)</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 2201)</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eskisehir Osmangazi Unv. Tip Fakultesi ( Site 2202)</name>
      <address>
        <city>Eskisehir</city>
        <zip>26480</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBU Sariyer Hamidiye Etfal Egitim ve Arastirma Hastanesi ( Site 2203)</name>
      <address>
        <city>Istanbul</city>
        <zip>34453</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI Dnipropetrovsk Regional Children Clinical Hospital DOR ( Site 2452)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PI Kryvorizka city clinical hospital 8 ( Site 2458)</name>
      <address>
        <city>Kryvyy Rig</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>50082</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Children Clinical Hospital ( Site 2461)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Children Specialised Hospital OHMADYT MOH Ukraine ( Site 2459)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>01135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution City Children s Clinical Hospital of Poltava City Council ( Site 2454)</name>
      <address>
        <city>Poltava</city>
        <state>Poltavska Oblast</state>
        <zip>36004</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsya Regional Children Clinical Hospital ( Site 2463)</name>
      <address>
        <city>Vinnytsya</city>
        <state>Vinnytska Oblast</state>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <disposition_first_submitted>January 19, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>February 26, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 4, 2021</disposition_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Ceftolozane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

